The chief financial officer of Ocugen just put his own money on the line, purchasing 21,000 shares at $1.23 apiece days before the company reports second-quarter earnings on August 6. Insider purchases at beaten-down biotechs rarely guarantee a turnaround, but they do force a closer look at what the market might be missing.
Right now, the market is missing quite a bit. Ocugen’s stock closed at €1.05, down 3.84% in a single session, and has shed roughly 21% over the past month. The 50-day moving average of €1.18 sits nearly 12% above the current price, underscoring just how sharp the recent selloff has been. The relative strength index has slipped to 33.4, brushing against the oversold threshold of 30. Yet beneath this technical weakness, the company’s pipeline is quietly advancing toward several high-stakes milestones.
Three Programs, One Tight Timeline
The August 6 earnings call at 8:30 a.m. Eastern time will arrive at a pivotal moment. Ocugen is running three parallel gene therapy programs, each targeting inherited retinal diseases, and each approaching a regulatory inflection point.
The lead candidate, OCU400 for retinitis pigmentosa, is furthest along. Phase 3 data are expected in the first quarter of 2027, and Ocugen plans to initiate a rolling Biologics License Application with the FDA in the third quarter of 2026, with completion targeted by the second quarter of 2027. That timeline would put a potential approval decision roughly a year from now.
For the Stargardt disease program, OCU410ST, an interim readout is scheduled for the third quarter of 2026, with a regulatory submission planned for mid-2027. And OCU410, the geographic atrophy candidate, received a significant boost on July 30 when the FDA granted it Regenerative Medicine Advanced Therapy (RMAT) status, clearing the way for a Phase 3 trial that is expected to begin in the third quarter of 2026.
The RMAT Advantage That Markets Are Ignoring
The RMAT designation for OCU410 is more than a procedural checkbox. It signals that the FDA views the Phase 2 data — which showed both clinical efficacy and a favorable safety profile — as sufficiently compelling to warrant an accelerated development path. The designation allows for more frequent interactions with the agency and could shorten the review timeline for a potential approval filing planned for 2028.
OCU410 is designed as a one-time subretinal injection, a structural advantage over existing therapies that require repeated intravitreal injections. For a patient population with geographic atrophy secondary to dry age-related macular degeneration, the difference between a single procedure and a lifetime of quarterly office visits is substantial. The market opportunity is correspondingly large, yet Ocugen’s current market capitalization of €368.61 million suggests investors are pricing in little of that potential.
Should investors sell immediately? Or is it worth buying Ocugen?
A $130 Million Cushion — With a Dilution Price Tag
To fund these three programs simultaneously, Ocugen raised $130 million in May 2026 through a convertible note offering carrying a 6.75% interest rate. The capital is intended to extend the company’s runway into 2028, covering the Phase 3 study of OCU410, the rolling BLA for OCU400, and the Stargardt program through its submission.
Convertible debt is a double-edged sword. It provides the liquidity needed to reach critical data readouts without the immediate pressure of an equity offering, but it also introduces dilution risk when the notes are eventually converted. For a micro-cap biotech with a monthly volatility of 66%, the market’s sensitivity to any financing news is understandable. Still, the alternative — running out of cash before pivotal data — would be far worse.
International Expansion Adds Another Layer
Ocugen is also diversifying geographically. In July 2026, the company signed a binding term sheet with Roots Pharmaceutical to license OCU400 for retinitis pigmentosa in the MENA region. The deal reduces reliance on the North American market and, if executed well, could provide non-dilutive revenue streams down the line.
The Analyst Gap
The disconnect between Ocugen’s stock price and its pipeline progress is perhaps best captured by the analyst consensus. The average price target stands at €10.04, implying upside of roughly 867% from current levels. Such targets are common in early-stage biotech and should be taken with a grain of salt, but the sheer magnitude of the gap suggests that either the analysts are overly optimistic or the market is overly pessimistic.
What to Watch on August 6
The second-quarter earnings report will provide the next concrete test. Investors will be looking for updates on the rolling BLA for OCU400, the interim analysis for OCU410ST, and the transition of OCU410 into Phase 3. The call will also clarify the company’s cash burn rate following the convertible note raise.
For now, Ocugen’s stock is behaving as if the pipeline were stalled, when in fact all three programs are accelerating. The insider purchase by the CFO doesn’t change the fundamental risk — these are still clinical-stage assets with no approved products and a long path to revenue. But it does suggest that someone inside the company sees value at these levels. Whether the broader market will eventually agree is a question that the next several quarters will answer.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from July 30 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 30.
Ocugen: Buy or sell? Read more here...
